Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Phase II Study of Temsirolimus and Lenalidomide in Patients with Relapsed and Refractory Lymphomas: Final Analysis of NCI 8309

Justin Kline, MD, Aaron P. Rapoport, MD, Adam M. Petrich, MD, Kenneth S. Cohen, MD, Sachdev P. Thomas, MD, Sreenivasa Nattam, MD, Krishna Rao, MD, Bethany Sleckman, MD, Walter Stadler, MD, Theodore Karrison, PhD, Sonali M. Smith, MD

Blood (2016) 128 (22): 4147.

https://doi.org/10.1182/blood.V128.22.4147.4147

Published: 2016

Journal Articles

Selective MEK Inhibition with AZD-6244 (selumetinib) in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): A University of Chicago Phase II Consortium Trial

Natalie Galanina, MD, Sonali M. Smith, MD, Chuanhong Liao, PhD, Adam M. Petrich, MD, Bernadette Libao, Ron Gartenhaus, MD, Jason R Westin, MD, Kenneth S. Cohen, MD, James Knost, MD, Walter Stadler, MD, Austin Doyle, MD, Theodore Karrison, PhD, Leo I. Gordon, MD, Andrew M Evens, DO, MS

Blood (2015) 126 (23): 3990.

https://doi.org/10.1182/blood.V126.23.3990.3990

Published: 2015

Journal Articles

CD34+ Circulating Progenitor Cell Frequency Is Highly Heritable

Kenneth S. Cohen, MD, Susan Cheng, MD, Martin G. Larson, ScD, L. Adrienne Cupples, PhD, Elizabeth L. McCabe, MS, Ying A. Wang, PhD, Roderick P. Martin, ALB, Rachael J. Klein, MS, Basma Hashmi, BS, Christopher J. O'Donnell, MD, Vasan S. Ramachandran, MD, Stanley Y. Shaw, MD, PhD, Thomas J. Wang, MD

Blood (2010) 116 (21): 4309.

https://doi.org/10.1182/blood.V116.21.4309.4309

Published: 2010

Journal Articles

Alemtuzumab-Containing Allogeneic Hematopoietic Cell Transplant (HCT) for Relapsed Lymphomas: Prognostic Factors and Outcome.

Vaishalee P. Kenkre, MD, Sarah Horowitz, Sonali M. Smith, MD, Andrew Artz, MD, MS, Kenneth S. Cohen, MD, Lucy A Godley, M.D., Ph.D., Justin Kline, M.D., Wendy Stock, MD, Koen van Besien, MD

Blood (2009) 114 (22): 2247.

https://doi.org/10.1182/blood.V114.22.2247.2247

Published: 2009

Journal Articles

Autologous Bone Marrow Transplant after Failed Peripheral Blood Stem Cell Mobilization Does Not Adversely Affect Engraftment or Transplant Related Toxicity.

B. Rioux-Masse, MD, J. Roy, MD, R. Belanger, MD, D.C. Roy, MD, L. Busque, MD, D. Fish, MD, G. Sauvageau, MD, T. Kiss, MD, S. Cohen, MD

Blood (2005) 106 (11): 2736.

https://doi.org/10.1182/blood.V106.11.2736.2736

Published: 2005

NARROW

Phase II Study of Temsirolimus and Lenalidomide in Patients with Relapsed and Refractory Lymphomas: Final Analysis of NCI 8309

Selective MEK Inhibition with AZD-6244 (selumetinib) in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): A University of Chicago Phase II Consortium Trial

CD34+ Circulating Progenitor Cell Frequency Is Highly Heritable

Alemtuzumab-Containing Allogeneic Hematopoietic Cell Transplant (HCT) for Relapsed Lymphomas: Prognostic Factors and Outcome.

Autologous Bone Marrow Transplant after Failed Peripheral Blood Stem Cell Mobilization Does Not Adversely Affect Engraftment or Transplant Related Toxicity.

Email alerts

ASH Publications

American Society of Hematology

Phase II Study of Temsirolimus and Lenalidomide in Patients with Relapsed and Refractory Lymphomas: Final Analysis of NCI 8309

Selective MEK Inhibition with AZD-6244 (selumetinib) in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): A University of Chicago Phase II Consortium Trial

CD34+ Circulating Progenitor Cell Frequency Is Highly Heritable

Alemtuzumab-Containing Allogeneic Hematopoietic Cell Transplant (HCT) for Relapsed Lymphomas: Prognostic Factors and Outcome.

Autologous Bone Marrow Transplant after Failed Peripheral Blood Stem Cell Mobilization Does Not Adversely Affect Engraftment or Transplant Related Toxicity.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only